Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 9, 2009, Pages 3157-3162

  Bourcier, Matthew E ^a,b   Sherrod, Amanda ^a   DiGuardo, Margaret ^a   Vinik, Aaron I ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZOXIDE; INSULIN; OCTREOTIDE; PENTETREOTIDE; PHENYTOIN; RAPAMYCIN;

AGED; ARTICLE; CASE REPORT; CONTINUOUS INFUSION; DISEASE SEVERITY; GLUCOSE INFUSION; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULINOMA; LABORATORY TEST; MALE; METASTASIS; PRIORITY JOURNAL; QUALITY OF LIFE;

MAMMALIA;

EID: 69949100179     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0788     Document Type: Article

References (30)

1. Fajans SS, Vinik AI 1989 Insulin-producing islet cell tumors. Endocrinol Metab Clin North Am 18:45-74
2. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, Service FJ 2009 Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 94:709-728
3. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419 (Pubitemid 15018832)
4. Ono T, Shiga N, Taneda Y, Umemura S 1999 The fasting-plasma glucose range in which insulin resistance measured by homeostasis assessment correlates with euglycemic clamping. J Jpn Diabetes Soc 42:1005-1011 (Pubitemid 30079961)
5. Fajans SS, Floyd Jr JC, Knopf RF, Rull J, Guntsche EM, Conn JW 1966 Benzothiadiazine suppression in insulin release from normal and abnormal islet cell tissue in man. J Clin Invest 45:481-492
6. Fajans SS, Floyd Jr JC, Thiffault CA, Knopf RF, Harrison TS, Conn JW 1968 Further studies on diazoxide suppression of insulin release from abnormal and islet tissue in man. Ann NY Acad Sci 150:261-280
7. Luna B, Feinglos MN 2001 Drug-induced hyperglycemia. JAMA 286:1945-1948
8. Stefanini P, Carboni M, Patrassi N, Basoli A 1974 β-Islet cell tumors of the pancreas: results of a study on 1,067 cases. Surgery 75:597-609
9. Altszuler N, Moraru E, Hampshire J 1977 On the mechanism of diazoxide-induced hyperglycemia. Diabetes 26:931-935
10. Ulbrecht JS, Schmeltz R, Aarons JH, Greene DA 1986 Insulinoma in a 94-year-old woman: long-term therapy with verapamil. Diabetes Care 9:186-188 (Pubitemid 16080475)
11. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D 1992 Stretozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519-523
12. Cheng PN, Saltz LB 1999 Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86:944-948
13. Rivera E, Ajani JA 1998 Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 21:36-38 (Pubitemid 28092969)
14. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC 2004 Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762-4771
15. Chu QD, Hill HC, Douglass Jr HO, Driscoll D, Smith JL, Nava HR, Gibbs JF 2002 Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 9:855-862 (Pubitemid 35265635)
16. Isacoff WH, Moss RA, Pecora AL, Fine RL 2006 Temozolomide/capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review. American Society of Clinical Oncology Annual Meeting Proceedings, part 1 (Abstract 14023). J Clin Oncol 24:18S (June 20 Supplement)
17. Sadoff L 1973 Control of hypoglycemia with L-asparaginase in a patient with islet cell cancer. J Clin Endocrinol Metab 36:334-337
18. Warne GL, Adie R, Hansky J, Martin FI, Varigos G 1975 Prolonged control of hypoglycaemia by L-asparaginase in islet cell carcinoma producing insulin and gastrin. Aust N Z J Med 5:466-468
19. Wullschleger S, Loewith R, Hall MN 2006 TOR signaling in growth and metabolism. Cell 124:471-484
20. Wang L, Ignat A, Axiotis CA 2002 Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl Immunohistochem Mol Morphol 10:139-146 (Pubitemid 34553170)
21. Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, Heitz PU, Eng C 2000 Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 157:1097-1103 (Pubitemid 30757931)
22. Yao JC 2007 Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab 21:163-172
23. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F 2008 Efficacy of RAD001 (everolimus) and Octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26:4311-4318
24. Van Gompel JJ, Chen H 2004 Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells. Surgery 136:1297-1302 (Pubitemid 39647548)
25. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G, Seufferlein T 2000 Insulin-like growth factor-1 is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 60:4573-4581 (Pubitemid 32103642)
26. Hobday TJ, Rubin J, Goldberg R, Erlichman C, Lloyd R 2003 Molecular markers in metastatic gastrointestinal neuroendocrine tumors. Proc Am Soc Clin Oncol 22:269 (Abstract 1078)
27. Leibowitz G, Cerasi E, Ketzinel-Gilad M 2008 The role of mTOR in the adaptation and failure of β-cells in type 2 diabetes. Diabetes Obes Metab 10:157-169
28. Di Paolo S, Teutonico A, Leogrande D, Capobianco C, Schena PF 2006 Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes? J Am Soc Nephrol 17:2236-2244
29. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J, Berthault MF, Magnan C, Cerasi E, Kaiser N, Leibowitz G 2008 mTOR inhibition by rapamycin prevents β-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57:945-957
30. Bussiere CT, Lakey JR, Shapiro AM, Korbutt GS 2006 The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 49:2341-2349